Toyo Kohan Co., Ltd.

Yamaguchi University

Ryouichi Tsunedomi

Shoichi Hazama

Masaaki Oka

Hirofumi Yamano

Shuichi Kamei

Mitsuyoshi Oba

Hiroaki Nagano

Yoshihiko Hamamoto

Toshiya Tsuda

Mayuko Hosoya

Yusuke Fujita

Hideyasu Matsuyama

Yoshiaki Yamamoto

Yukiha Ishikawa

An object of the present invention is to provide a simple and efficient device for predicting a risk of occurrence of a side effect of irinotecan by analyzing a single nucleotide polymorphism in a region encoding a specific gene. The prediction of the risk of the occurrence of a side effect of irinotecan is assisted by analyzing a single nucleotide polymorphism in a region encoding the APCDD1L gene, the R3HCC1 gene, the OR51I2 gene, the MKKS gene, the EDEM3 gene, or the ACOX1 gene which are present on genomic DNA in a biological sample collected from a test subject; or a single nucleotide polymorphism which is in linkage disequilibrium with or genetically linked to the single nucleotide polymorphism, and determining whether the single nucleotide polymorphism is homozygous for a variant type, heterozygous, or homozygous for a wild-type.

Method for assisting prediction of risk of occurrence of side effect of irinotecan

It is intended to conveniently determine the pharmacokinetics of axitinib and to predict the therapeutic effect of axitinib. The present invention provides a method for determining the pharmacokinetics of axitinib, comprising the step of calculating a predicted pharmacokinetic parameter of axitinib using specific gene polymorphisms and background factors regarding a test subject.

Method for determining pharmacokinetics of axitinib and method for predicting therapeutic effect of axitinib based on pharmacokinetics of axitinib

A therapeutic effect of irinotecan is predicted using a predetermined genetic polymorphism. A genetic polymorphism identified by rs1980576 in APCDD1L gene, or a genetic polymorphism in linkage disequilibrium with the above genetic polymorphism is analyzed, and determination is performed based on the genotype of the genetic polymorphism.

Method for predicting therapeutic effects of irinotecan, and kit for same

In the case of using a blocking nucleic acid to prevent non-specific hybridization of a target nucleic acid with a nucleic acid probe, further excellent efficiency of detecting the target nucleic acid is achieved. A buffer composition used in hybridization of a target nucleic acid with a nucleic acid probe, wherein the buffer composition for hybridization contains a blocking nucleic acid comprising a nucleotide sequence complementary to a region comprising at least a non-detection target nucleotide in a non-target nucleic acid, in a concentration of one or more times higher than the concentration of a nucleic acid in a nucleic acid mixture consisting of the target nucleic acid and the non-target nucleic acid.

Buffer composition for hybridization and hybridization method

A buffer composition for hybridization of a target nucleic acid is provided. The nucleic acid can include a nucleotide to be detected with a nucleic acid probe. The probe can contain a nucleotide sequence complementary to the target nucleic acid. The buffer can include a blocking nucleic acid having a nucleotide sequence complementary to a non-target nucleic acid having a nucleotide not to be detected corresponding to the nucleotide to be detected. The buffer composition can suppress non-specific hybridization to the nucleic acid probe even when a non-target nucleic acid is present. The use of the buffer composition can achieve excellent detection efficiency of the target nucleic acid.

Buffer composition for hybridization use, and hybridization method

Growing community of inventors

Ube, Japan

Ryouichi Tsunedomi